The Vaccibody Vaccine Technology Platform has the potential to overcome the challenges faced in today’s vaccine development through rational and innovative design. Vaccibody’s vaccines are based on thorough understanding of the immunological principles and physiological mechanisms:
Vaccibody vaccines can direct the immune response in an optimal manner by specifically targeting Antigen Presenting Cells (APC), known to be essential to initiate an effective immune response.
By intelligent design Vaccibody vaccines are tailored to induce the desired immune response profile for each specific disease with any given antigen.
The unique efficacy of Vaccibody’s Vaccine Technology Platform offers the possibility to develop vaccines to treat cancers. Vaccibody is currently in clinical phase I/IIa with a therapeutic HPV16-vaccine to treat precancerous cervical lesions.
Novel product candidates aimed at playing an important role in future immunotherapy is under development.